Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial

Marker Therapeutics, Inc.

Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.
APOLLO study previously reported 78% objective response (7/9) and 44% complete response (4/9) at 4 weeks post MT-601 infusion.
Cellipont to provide technology transfer and cGMP manufacturing services over approximately nine months to support clinical supply.
Collaboration designed to enable potential pivotal trial and commercial readiness; Cellipont facility in The Woodlands, TX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.